Edmond Chipumuro

1.8k total citations · 1 hit paper
14 papers, 930 citations indexed

About

Edmond Chipumuro is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Edmond Chipumuro has authored 14 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 3 papers in Neurology and 3 papers in Oncology. Recurrent topics in Edmond Chipumuro's work include RNA Research and Splicing (4 papers), Protein Degradation and Inhibitors (4 papers) and RNA modifications and cancer (3 papers). Edmond Chipumuro is often cited by papers focused on RNA Research and Splicing (4 papers), Protein Degradation and Inhibitors (4 papers) and RNA modifications and cancer (3 papers). Edmond Chipumuro collaborates with scholars based in United States and Germany. Edmond Chipumuro's co-authors include Nicholas Kwiatkowski, Tinghu Zhang, Bandana Sharma, Nathanael S. Gray, Rani E. George, Guo‐Cheng Yuan, Richard A. Young, Kwok‐Kin Wong, Camilla L. Christensen and Caleb M. Yeung and has published in prestigious journals such as Cell, Nature Communications and PLoS ONE.

In The Last Decade

Edmond Chipumuro

13 papers receiving 918 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

2014 451 citations Edmond Chipumuro, Eugenio Marco et al. Cell profile →

Peers

Countries citing papers authored by Edmond Chipumuro

Since Specialization

Citations

This map shows the geographic impact of Edmond Chipumuro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edmond Chipumuro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edmond Chipumuro more than expected).

Fields of papers citing papers by Edmond Chipumuro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edmond Chipumuro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edmond Chipumuro. The network helps show where Edmond Chipumuro may publish in the future.

Co-authorship network of co-authors of Edmond Chipumuro

This figure shows the co-authorship network connecting the top 25 collaborators of Edmond Chipumuro. A scholar is included among the top collaborators of Edmond Chipumuro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edmond Chipumuro. Edmond Chipumuro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines 2024 ·Cancer Research Communications ·Anne E. Dodson, Sol Shenker, Pamela Sullivan, Sumeet U. Nayak, (unknown), Michael McGuire, Edmond Chipumuro, (unknown), Erica R. Tobin, (unknown), Andrew A. Wylie, Dipen Sangurdekar	1
2	Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers 2020 ·European Journal of Cancer ·(unknown), (unknown), Richard Sullivan, (unknown), Sol Shenker, Michael McGuire, Paula Grasberger, Kerstin W. Sinkevicius, Nafeeza Hafeez, Gavin Histen, Edmond Chipumuro, Julie A. Hixon, Elizabeth A. Krall, (unknown), Johannes H.W. de Wilt, Michael R. Schlabach, Frank Stegmeier, Andrew Olaharski, Andrew A. Wylie	15
3	CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation 2019 ·Nature Communications ·Małgorzata Krajewska, Ruben Dries, Andrew V. Grassetti, (unknown), Yang Gao, Hao Huang, Bandana Sharma, Daniel S. Day, Nicholas Kwiatkowski, (unknown), (unknown), Edmond Chipumuro, Tinghu Zhang, Arno L. Greenleaf, Guo‐Cheng Yuan, Nathanael S. Gray, Richard A. Young, Matthias Geyer, Scott A. Gerber, Rani E. George	181
4	Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors 2017 ·Cell chemical biology ·Yang Gao, Tinghu Zhang, Hideki Terai, Scott B. Ficarro, Nicholas Kwiatkowski, (unknown), Bandana Sharma, Camilla L. Christensen, Edmond Chipumuro, Kwok‐Kin Wong, Jarrod A. Marto, Peter S. Hammerman, Nathanael S. Gray, Rani E. George	56
5	MiR-338-3p regulates neuronal maturation and suppresses glioblastoma proliferation 2017 ·PLoS ONE ·(unknown), (unknown), (unknown), Gilbert J. Rahme, Edmond Chipumuro, (unknown), Julia F. Litzky, L. Benjamin Hills, (unknown), Patrick D. Skelton, Bryan W. Luikart	33
6	Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin 2016 ·Molecular Cancer Therapeutics ·Shanthi Ganesh, Martin L. Koser, (unknown), (unknown), Junyan Tao, (unknown), Bo Ying, Dongyu Chen, (unknown), Edmond Chipumuro, Zakir Siddiquee, (unknown), Cheng-Jung Lai, Henryk Dudek, Satdarshan P. Monga, Weimin Wang, Bob D. Brown, Marc Abrams	50
7	Abstract 3827: Preclinical characterization of DCR-BCAT as a component of combination therapy 2016 ·Cancer Research ·Shanthi Ganesh, (unknown), Martin L. Koser, (unknown), Edmond Chipumuro, Zakir Siddiquee, (unknown), (unknown), Dongyu Chen, (unknown), (unknown), Weimin Wang, Robert Brown, Marc Abrams	0
8	Abstract 2925: Anti-tumor activity of a MYC-targeting dicer substrate siRNA in combination with BRD4/CDK7 inhibitors 2016 ·Cancer Research ·Edmond Chipumuro, Zakir Siddiquee, Shanthi Ganesh, (unknown), (unknown), Bo Young Kim, Dongyu Chen, (unknown), (unknown), Weimin Wang, (unknown), (unknown), Marc Abrams, Robert Brown	5
9	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer 2014 ·DSpace@MIT (Massachusetts Institute of Technology) ·Edmond Chipumuro, Eugenio Marco, Camilla L. Christensen, Tinghu Zhang, Clark M. Hatheway, Bandana Sharma, Caleb M. Yeung, Abigail Altabef, Antonio R. Pérez‐Atayde, Kwok‐Kin Wong, Guo‐Cheng Yuan, Nathanael S. Gray, Rani E. George, (unknown), Brian J. Abraham, Richard A. Young	1
10	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer breakdown → 2014 ·Cell ·Edmond Chipumuro, Eugenio Marco, Camilla L. Christensen, Nicholas Kwiatkowski, Tinghu Zhang, Clark M. Hatheway, Brian J. Abraham, Bandana Sharma, Caleb M. Yeung, Abigail Altabef, Antonio R. Pérez‐Atayde, Kwok‐Kin Wong, Guo‐Cheng Yuan, Nathanael S. Gray, Richard A. Young, Rani E. George	451
11	The ubiquitin hydrolase, USP22 contributes to 3’-end processing of JAK-STAT inducible genes 2013 ·Epigenetics & Chromatin ·Edmond Chipumuro, Melissa A. Henriksen	1
12	The ubiquitin hydrolase USP22 contributes to 3'‐end processing of JAK‐STAT‐inducible genes 2011 ·The FASEB Journal ·Edmond Chipumuro, Melissa A. Henriksen	32
13	Menin and RNF20 recruitment is associated with dynamic histone modifications that regulate signal transducer and activator of transcription 1 (STAT1)-activated transcription of the interferon regulatory factor 1 gene (IRF1) 2010 ·Epigenetics & Chromatin ·(unknown), Edmond Chipumuro, Melissa A. Henriksen	27
14	Sequencing and analysis of the gene-rich space of cowpea 2008 ·BMC Genomics ·Michael P. Timko, Paul J. Rushton, (unknown), (unknown), Edmond Chipumuro, Foo Cheung, Christopher D. Town, Xianfeng Chen	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact